Please select the option that best describes you:
Topics:
Gastrointestinal Cancers • Medical Oncology • Liver and Pancreas Tumors • NCI-CCC Tumor Board Question • Internal Medicine • Rutgers • Gastroenterology • General Hepatology
Are you routinely using thrombopoietin agonists in patients with hep C and HCC?
If so, for what platelet count threshold and do you have a preference as to which agent?
Answer from: Medical Oncologist at Community Practice
Thrombocytopenia is a common issue in patients with advanced liver disease due to decreased thrombopoietin production and hypersplenism sequestration from portal hypertension. The degree of thrombocytopenia is often a maker of both severity of liver disease.There are several TPO agonists on the mark...
Sign in or Register to read more